EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization

Jenna R Puttkammer iD, Jason N Barreto iD, Chelsee J Jensen iD, Adrienne N Nedved iD, Justine L Wilson-Miller, Kristin C Cole, Lucy M Holmes, Allison R Kosobud, Prashant Kapoor iD, Morie A Gertz iD, David Dingli, Wilson I Gonsalves iD und 8 weitere

JCO Oncology Practice · 2026-01 · 22 (1) · 83-90

DOI: 10.1200/op-24-00930 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Oncology Practice, 2026-01. Verfasst von Jenna R Puttkammer und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, Cytokine Release Syndrome, Ambulatory Care. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Cytokine release syndrome (CRS) of any grade occurs in 56%-80% of bispecific antibodies (BsAbs) used in multiple myeloma (MM). Risk mitigation strategies are required to expedite escalation of care if toxicities develop. The rarity of grade 3 or 4 CRS compels protocolized outpatient management of BsAbs as outpatient practice may avoid hospital admissions and costly resource utilization without compromising safety. MATERIALS AND METHODS Patients with MM who received BsAb step-up dosing (SUD) from August 23, 2023, to March 29, 2024, were enrolled. Baseline demographics, patient outcomes, and CRS management were reviewed to assess the safety of outpatient practice. Resource utilization was also analyzed. RESULTS In this study, 34 patients received outpatient SUD of BsAbs (teclistamab n = 17, talequetamab n = 17) with 16 remaining outpatient throughout the entire SUD period. CRS occurred in seven patients who did not require hospitalization, demonstrating the safety of outpatient management of BsAb toxicity, regardless of low-grade CRS. CRS was observed in 24 patients (maximum grade 2) and immune effector cell–associated neurotoxicity syndrome in four patients (maximum grade 3). All patients with CRS received steroids, including 12 patients at home when instructed. Tocilizumab was given to 13 patients, accounting for 18 doses. If all doses of BsAbs and tocilizumab were given outpatient, the medication margin would be $115,004 in US dollars (USD). CONCLUSION An outpatient-based practice for BsAb administration demonstrated safety and cost savings. The description of our practice and results of this study provide valuable insights into the safety, feasibility, and resource stewardship of outpatient management of BsAbs. Future research should attempt to predict and stratify CRS risk to deliver a tailored supportive strategy and continued increase of outpatient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple MyelomaCytokine Release SyndromeAmbulatory CareHumansMaleFemaleMiddle AgedAgedOutpatientsAdultAged, 80 and over

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Rochester, MN.
  • Department of Finance, Mayo Clinic, Rochester, MN.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
  • Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN.

ORCID-Profile: Jenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, Adrienne N Nedved, Prashant Kapoor, Morie A Gertz, Wilson I Gonsalves, Shaji K Kumar, Rahma Warsame, Moritz Binder, Joselle Cook, Yi Lin, Tyler B Sandahl

Zitieren

APA

Puttkammer, J. R., Barreto, J. N., Jensen, C. J., Nedved, A. N., Wilson-Miller, J. L., Cole, K. C., Holmes, L. M., Kosobud, A. R., Kapoor, P., Gertz, M. A., Dingli, D., Gonsalves, W. I., Kumar, S. K., Hayman, S. R., Kourelis, T. V., Warsame, R., Binder, M., Cook, J., Lin, Y., & Sandahl, T. B. (2026). Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization. JCO Oncology Practice, 22(1), 83-90. https://doi.org/10.1200/op-24-00930

Vancouver

Puttkammer JR, Barreto JN, Jensen CJ, Nedved AN, Wilson-Miller JL, Cole KC, et al. Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization. JCO Oncology Practice. 2026;22(1):83-90. doi:10.1200/op-24-00930

BibTeX
@article{Puttkammer2026,
  author = {Puttkammer, Jenna R and Barreto, Jason N and Jensen, Chelsee J and Nedved, Adrienne N and Wilson-Miller, Justine L and Cole, Kristin C and Holmes, Lucy M and Kosobud, Allison R and Kapoor, Prashant and Gertz, Morie A and Dingli, David and Gonsalves, Wilson I and Kumar, Shaji K and Hayman, Suzanne R and Kourelis, Taxiarchis V and Warsame, Rahma and Binder, Moritz and Cook, Joselle and Lin, Yi and Sandahl, Tyler B},
  title = {Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization},
  journal = {JCO Oncology Practice},
  year = {2026},
  volume = {22},
  number = {1},
  pages = {83--90},
  doi = {10.1200/op-24-00930}
}
Kostenlos starten →